Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection

Journal of Clinical Virology

Volumn 36, Issue 4, 2006, Pages 283-291

  Hornberger, John ^a,b,c   Torriani, Francesca J ^d   Dieterich, Douglas T ^e   Bräu, Norbert ^b   Sulkowski, Mark S ^f   Torres, Maribel Rodriguez ^g,h   Green, Jesse ⁱ   Patel, Kavita ⁱ  

^a Acumen LLC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g Fundacion de Investigacion de Diego   (United States)

^h PONCE SCHOOL OF MEDICINE   (Puerto Rico)

ⁱ HOFFMANN LA ROCHE INC   (United States)

Author keywords

Cost effectiveness; Costs; Economics; HIV; Interferon; Peginterferon alfa 2a; Ribavirin

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; VIROLOGY; VIRUS GENOME;

AGE DISTRIBUTION; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MARKOV CHAINS; MODELS, ECONOMIC; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; TREATMENT OUTCOME; UNITED STATES;

EID: 33746026313     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.04.008     Document Type: Article

References (46)

1. Backus L., Phillips B., Boothroyd B., Mole L., Burgess J., Rigsby M., et al. Hepatitis C co-infection increases mortality in HIV-infected veterans treated with highly active antiretroviral therapy (abstract no. 800). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11 (2004)
2. Bennett W.G., Inoue Y., Beck J.R., Wong J.B., Pauker S.G., and Davis G.L. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127 (1997) 855-865
3. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
4. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 (2004) 2839-2848
5. Chong C.A., Gulamhussein A., Heathcote E.J., Lilly L., Sherman M., Naglie G., et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 98 (2003) 630-638
6. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al., Team ACTGAS. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New Engl J Med 351 (2004) 451-459
7. de Jongh F., Jannsen H., de Man R., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103 (1992) 1630-1635
8. Detels R., Munoz A., McFarlane G., Kingsley L.A., Margolick J.B., Giorgi J., et al., Multicenter AIDS Cohort Study Investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 280 (1998) 1497-1503
9. DMD America. Analy$ource Online. Available online at: www.analysource.com/Analy$ource.pdf. Accessed: 1 December 2004.
10. Fattovich G., Giustina G., Degos F., Diodati G., Tremolada F., Nevens F., et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 27 (1997) 201-205
11. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., and Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
12. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 347 (2002) 975-982
13. Garber A. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Available online at: http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.284v1. Accessed: 14 May 2004.
14. Garber A.M., and Phelps C.E. Economic foundations of cost-effectiveness analysis. J Health Econ 16 (1997) 1-31
15. Gold M., Siegel J., Russell L., and Weinstein M. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
16. Graham C.S., Baden L.R., Yu E., Mrus J.M., Carnie J., Heeren T., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33 (2001) 562-569
17. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
18. Jaggy C., von Overbeck J., Ledergerber B., Schwarz C., Egger M., Rickenbach M., et al., Swiss HIVCS. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 362 (2003) 877-878
19. Kim W.R., Poterucha J.J., Hermans J.E., Therneau T.M., Dickson E.R., Evans R.W., et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 127 (1997) 866-874
20. Kim W.R., Poterucha J.J., and Gross Jr. J.B. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. Hepatology 31 (2000) 807-808
21. Kuehne F., Bethe U., Freedberg K., and Goldie S. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 162 (2002) 2545-2556
22. Lipscomb J., Weinstein M., and Torrence G. Time preference. In: Gold M., et al. (Ed). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York, NY 214-246
23. Marschner I., Collier A., Coombs R., D'Aquila R., DeGruttola V., Fischl M., et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 117 (1998) 40-47
24. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16 (1997) 33-64
25. Meltzer D. Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J Health Econ 20 (2001) 109-129
26. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P., et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135 (2001) 17-26
27. National Cancer Institute. Surveillance and Epidemiology End Results Program Seer*Stat public-use files; 2003.
28. National Center for Health Statistics. Vital statistics of the United States, 1997, vol. 2. Mortality, Part A; 1998.
29. Neumann P.J., Rosen A.B., and Weinstein M.C. Medicare and cost-effectiveness analysis. N Engl J Med 353 (2005) 1516-1522
30. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
31. Pinkerton S.D., and Holtgrave D.R. How HIV treatment advances affect the cost-effectiveness of prevention. Med Decis Making 20 (2000) 89-94
32. Powderly W.G. Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. Clin Infect Dis 38 (2004) 1
33. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. International Society for Pharmacoeconomics and Outcomes Research. Available at http://www.ispor.org/workpaper/clinical_trial.asp; 2005.
34. Salomon J., Weinstein M., Hammitt J., and Goldie S. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 156 (2002) 761-773
35. Salomon J.A., Weinstein M.C., Hammitt J.K., and Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290 (2003) 228-237
36. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 13 (1993) 322-338
37. Sulkowski M., and Thomas D. Hepatitis C in the HIV-infected patient. Clin Liver Dis 7 (2003) 179-194
38. Sullivan S.D., Jensen D.M., Bernstein D.E., Hassanein T.I., Foster G.R., Lee S.S., et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 99 (2004) 1490-1496
39. Takahashi M., Yamada G., Miyamoto R., Doi T., Endo H., and Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 88 (1993) 240-243
40. Tedaldi E., Baker R., Moorman A., Alzola C., Furhrer J., McCabe R., et al., The HIV Outpatient Study (HOPS) Investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to Human Immunodeficiency Virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36 (2003) 363-367
41. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 351 (2004) 438-450
42. Tremolada F., Casarin C., Alberti A., Drago C., Tagger A., Ribero M., et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 16 (1992) 273-281
43. Ubel P.A., Hirth R.A., Chernew M.E., and Fendrick A.M. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 163 (2003) 1637-1641
44. Weinstein M.C., and Manning Jr. W.G. Theoretical issues in cost-effectiveness analysis. J Health Econ 16 (1997) 121-128
45. Younossi Z.M., Singer M.E., McHutchison J.G., and Shermock K.M. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30 (1999) 1318-1324
46. Zeuzem S., Diago M., Gane E., Reddy K.R., Pockros P., Prati D., et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127 (2004) 1724-1732